PriceTargets.com logo

Prelude Therapeutics - PRLD Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $10.40
  • Forecasted Upside: 84.07 %
  • Number of Analysts: 5
  • Breakdown:
  • 1 Sell Ratings
  • 2 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$5.65 As of 12/7/2022 03:56 PM ET
▼ -0.62 (-9.89%)

This chart shows the closing price for PRLD by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Prelude Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PRLD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PRLD

Analyst Price Target is $10.40
▲ +84.07% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Prelude Therapeutics in the last 3 months. The average price target is $10.40, with a high forecast of $15.00 and a low forecast of $6.00. The average price target represents a 84.07% upside from the last price of $5.65.

This chart shows the closing price for PRLD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 5 polled investment analysts is to hold stock in Prelude Therapeutics. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
6/15/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
9/13/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
12/12/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
3/12/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
6/10/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
9/8/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
11/7/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
12/7/2022

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/21/2022Bank of AmericaDowngradeNeutral ➝ Underperform$8.00 ➝ $6.00Low
11/17/2022HC WainwrightLower TargetBuy$16.00 ➝ $15.00Low
11/15/2022Morgan StanleyLower TargetEqual Weight$11.00 ➝ $10.00Low
9/9/2022Morgan StanleyDowngradeOverweight ➝ Equal Weight$19.00 ➝ $11.00Low
7/29/2022Jefferies Financial GroupInitiated CoverageBuy$9.00Low
5/12/2022HC WainwrightLower TargetBuy$62.00 ➝ $16.00High
3/17/2022Morgan StanleyLower TargetOverweight$20.00 ➝ $19.00High
3/15/2022Bank of AmericaDowngradeBuy ➝ Neutral$50.00 ➝ $10.00High
2/28/2022BarclaysDowngradeOverweight ➝ Equal Weight$20.00 ➝ $12.00High
11/17/2021BarclaysLower TargetOverweight$33.00 ➝ $20.00High
11/15/2021HC WainwrightReiterated RatingBuy$61.00High
10/8/2021Morgan StanleyUpgradeEqual Weight ➝ Overweight$60.00 ➝ $35.00Low
10/8/2021HC WainwrightReiterated RatingBuy$62.00High
10/8/2021BarclaysLower TargetOverweight$80.00 ➝ $33.00High
7/27/2021Bank of AmericaUpgradeNeutral ➝ Buy$60.00High
4/26/2021HC WainwrightInitiated CoverageBuy$62.00High
3/17/2021Morgan StanleyBoost TargetEqual Weight$47.00 ➝ $60.00Low
3/9/2021BarclaysInitiated CoverageOverweight$80.00High
12/16/2020Morgan StanleyBoost TargetEqual Weight$38.00 ➝ $47.00Medium
11/20/2020Bank of AmericaDowngradeBuy ➝ NeutralHigh
11/12/2020Morgan StanleyBoost TargetEqual Weight$34.00 ➝ $38.00Low
10/20/2020Bank of AmericaInitiated CoverageBuy$40.00High
10/20/2020Morgan StanleyInitiated CoverageEqual Weight$34.00High
10/20/2020The Goldman Sachs GroupInitiated CoverageNeutral$37.00High
(Data available from 12/7/2017 forward)

News Sentiment Rating

0.08 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/11/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
6/10/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/10/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/9/2022
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/8/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/8/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/7/2022
  • 1 very positive mentions
  • 5 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
12/7/2022

Current Sentiment

  • 1 very positive mentions
  • 5 positive mentions
  • 3 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Prelude Therapeutics logo
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; PRT3645, a brain penetrant molecule that potently and selectively targets CDK4/6; and PRT-K4 that is in preclinical stage for solid tumors. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.
Read More

Today's Range

Now: $5.65
Low: $5.65
High: $6.16

50 Day Range

MA: $6.87
Low: $6.12
High: $8.50

52 Week Range

Now: $5.65
Low: $3.87
High: $15.57

Volume

1,373 shs

Average Volume

61,696 shs

Market Capitalization

$270.24 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.35

Frequently Asked Questions

What sell-side analysts currently cover shares of Prelude Therapeutics?

The following Wall Street research analysts have issued reports on Prelude Therapeutics in the last twelve months: Bank of America Co., Barclays PLC, HC Wainwright, Jefferies Financial Group Inc., and Morgan Stanley.
View the latest analyst ratings for PRLD.

What is the current price target for Prelude Therapeutics?

5 Wall Street analysts have set twelve-month price targets for Prelude Therapeutics in the last year. Their average twelve-month price target is $10.40, suggesting a possible upside of 65.9%. HC Wainwright has the highest price target set, predicting PRLD will reach $15.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $6.00 for Prelude Therapeutics in the next year.
View the latest price targets for PRLD.

What is the current consensus analyst rating for Prelude Therapeutics?

Prelude Therapeutics currently has 1 sell rating, 2 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in PRLD, but not buy more shares or sell existing shares.
View the latest ratings for PRLD.

What other companies compete with Prelude Therapeutics?

Other companies that are similar to Prelude Therapeutics include Generation Bio, Heron Therapeutics, Ardelyx, OrganiGram and Aadi Bioscience. Learn More about companies similar to Prelude Therapeutics.

How do I contact Prelude Therapeutics' investor relations team?

The company's listed phone number is 302-467-1280 and its investor relations email address is [email protected] The official website for Prelude Therapeutics is www.preludetx.com. Learn More about contacing Prelude Therapeutics investor relations.